信华生物药业

Sino-High Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutic antibodies for oncology. Headquartered in Hangzhou, China, the company utilizes its proprietary high-throughput antibody discovery platform, which includes extensive fully human antibody libraries and advanced screening technologies. Its pipeline features several promising candidates, including bispecific antibodies targeting the PD-L1 and CD47 pathways to enhance anti-tumor immune responses. Sino-High's research strategy emphasizes the creation of differentiated biologics with improved safety and efficacy profiles compared to existing therapies. The company is led by a team of industry veterans with significant experience in global drug development and commercialization. Sino-High aims to address significant unmet medical needs in both solid tumors and hematological malignancies through its innovative R&D engine.